Related Experiment Video
Updated: Dec 28, 2025
Quantitating Iron Transport Across the Mouse Placenta In Vivo Using Nonradioactive Iron Isotopes
Published on: May 10, 2022
Use of deferoxamine (DFO) in transfusion-dependent β-thalassemia during pregnancy: A retrospective study
Maria Grazia Piccioni1, Carmela Capone1, Flaminia Vena1
1Department of Gynecological and Obstetric Sciences and Urological Sciences, University of Rome "Sapienza", Umberto I Hospital, V. le del Policlinico 155, 00161 Rome, Italy.
Objective:
To report cases of use of chelation therapy during pregnancy which resulted in favorable outcomes for the babies.
Materials And Methods:
In this retrospective cohort study, we described the evolution and outcome of 9 pregnancies in Italian thalassemic women who received deferoxamine (DFO) inadvertently during early pregnancy.
Results:
The use of deferoxamine during first trimester did not lead to adverse effects on the fetus or cause major complications for the gestation, although an increase in iron burden was observed after suspending chelation therapy.
Conclusion:
In our experience, iron-chelation therapy might be administrated in pregnancy where the benefits to the mother outweigh the potential risks to the baby.
More Related Videos
05:23Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload
Published on: March 14, 2017
11:59Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies
Published on: September 6, 2017
